Evidence map›Paper›PMID 39915492›Full record

ArticleNPJ vaccines2025

Author Correction: SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate.

Ernesto Luna, Sophie Ruiz, Marie Garinot, Cyril Chavagnac, Pankaj Agrawal, John Escobar, Laurent Revet, Marie-Jeanne Asensio, Fabienne Piras, Francis G Fang and 4 more

Abstract readPublished Erratum
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ernesto Luna *Sanofi Vaccines business unit, R&D, Orlando, FL, USA.
Sophie Ruiz *Sanofi Vaccines business unit, R&D, Marcy L'Etoile, France.ORCID http://orcid.org/0000-0002-1919-3100
Marie Garinot *Sanofi Vaccines business unit, R&D, Marcy L'Etoile, France.
Cyril ChavagnacSanofi Vaccines business unit, R&D, Marcy L'Etoile, France.ORCID http://orcid.org/0009-0001-2625-2842
Pankaj AgrawalSanofi Vaccines business unit, R&D, Orlando, FL, USA.
John EscobarSanofi Vaccines business unit, R&D, Orlando, FL, USA.
Laurent RevetSanofi Vaccines business unit, R&D, Marcy L'Etoile, France.
Marie-Jeanne AsensioSanofi Vaccines business unit, R&D, Marcy L'Etoile, France.
Fabienne PirasSanofi Vaccines business unit, R&D, Marcy L'Etoile, France.
Francis G FangEisai Inc, Cambridge, MA, USA.
Donald R DrakeSanofi Vaccines business unit, R&D, Orlando, FL, USA.
Bachra RokbiSanofi Vaccines business unit, R&D, Marcy L'Etoile, France.
Daniel LarocqueSanofi Vaccines business unit, R&D, Marcy L'Etoile, France.ORCID http://orcid.org/0000-0002-2514-3687
Jean HaenslerSanofi Vaccines business unit, R&D, Marcy L'Etoile, France. jean.haensler@sanofi.com.ORCID http://orcid.org/0000-0002-3471-973X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39915492
PMCPMC11802717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.